Arnica Montana Root Calcium Fluoride Calcium Iodid

證據等級: L5

預測適應症: 0 個

Multi-Component Botanical/Homeopathic Combination: Insufficient Data for Repurposing Analysis

One-Sentence Summary

This candidate is a complex 8-component botanical and mineral formula — including Arnica montana, Horse chestnut, Hedera helix, and Conium maculatum — with no registered indications and no US regulatory approval. The TxGNN model returned no predicted indications for this combination, as the multi-component structure prevented knowledge graph mapping. Without DrugBank linkage or a defined original indication, a standard repurposing evaluation cannot be completed at this stage.

Quick Overview

Item	Content
Original Indication	Not established (no registered indications found)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	Unassessable (model prediction not generated)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This candidate contains 8 distinct components:

Component	Class	Known Pharmacological Role
Arnica montana root	Botanical	Anti-inflammatory, wound healing
Calcium fluoride	Mineral	Homeopathic (connective tissue)
Calcium iodide	Mineral salt	Homeopathic
Clematis recta flowering top	Botanical	Homeopathic (rheumatic conditions)
Conium maculatum flowering top	Botanical	Alkaloid-bearing; historically sedative/antispasmodic
Hedera helix flowering twig	Botanical	Anti-inflammatory, traditionally respiratory
Horse chestnut	Botanical	Aescin — venous insufficiency, anti-edema
Scrophularia nodosa whole	Botanical	Traditional anti-inflammatory, lymphatic

The TxGNN model requires a single DrugBank ID to anchor the drug entity in the knowledge graph and generate disease-probability scores. Because this candidate is a multi-component formula with no unified DrugBank entry, the pipeline could not produce scored repurposing predictions.

Individually, several components have documented pharmacological rationale — Horse chestnut (Aesculus hippocastanum) has the strongest evidence base, with clinical data in chronic venous insufficiency. Arnica montana has anti-inflammatory and hematoma-resolving properties. The overall combination profile is consistent with a homeopathic or standardized complex herbal preparation targeting venous, lymphatic, or soft-tissue conditions — but this remains a pharmacological inference, not a model-derived prediction.

Safety Considerations

Standard safety databases returned no interactions or warnings for this combination as a whole. However, one component warrants special attention:

Conium maculatum (poison hemlock) contains coniine and related piperidine alkaloids. Even in diluted homeopathic formulations, the presence of this ingredient requires clarification of the actual dose and preparation standard before any clinical use.
Hedera helix may cause contact sensitization in some individuals.
No drug–drug interaction data is available for this combination from standard pharmacological sources.

Please refer to individual component monographs and applicable homeopathic/herbal regulatory guidance for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline could not generate repurposing predictions because the multi-component combination lacks a unified knowledge graph entity. Without a defined original indication and with critical MOA and safety data absent, this candidate cannot proceed through standard repurposing evaluation.

To proceed, the following is needed:

Decompose the combination: Run TxGNN predictions for each individual botanical component (e.g., Horse chestnut → Aesculus hippocastanum → DrugBank DB13566 equivalent) to identify which ingredient drives repurposing signal
Clarify formulation type: Confirm whether this is a homeopathic preparation (highly diluted, regulated under different standards) or a standardized herbal extract — these follow entirely different evidence and regulatory pathways
Obtain product label: Retrieve the original monograph or package insert to establish the intended indication and dosing context
Safety review for Conium maculatum: Determine the actual alkaloid content and concentration before any clinical consideration
Resubmit individual components: Once individual DrugBank IDs are confirmed, rerun the evidence pack pipeline per ingredient and aggregate results
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.